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ABSTRACT 
A series of 3-aryl-1-phenyl-1H-pyrazole derivatives was synthesized in good yield and as-
sayed in vitro as inhibitors of the mice acetylcholinesterase (AChE) and two goat liver mono-
amine oxidase (MAO) isoforms, MAO-A and MAO-B. Most of the compounds demonstrated 
a good AChE and selective MAO-B inhibitory activities in the nanomolar or low micromolar 
range. N-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-yl) methylene) benzenamine (3e, 
pIC50 = 4.2) and N-((4-fluorophenyl)-1-phenyl-1H-pyrazole-4-yl) methylene) methanamine 
(3f, pIC50 = 3.47) were the most potent AChE and highly selective MAO-B inhibitors respec-
tively. Structure activity relationships showed that chloro derivatives were more effective 
AChE inhibitors as compared to fluoro derivatives while reverse trend was observed in MAO-
B inhibitory activity. With the aid of modeling studies, potential binding orientations as well 
as interactions of the compounds in the AChE and MAO-B active sites were examined. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a chronic 
neurodegenerative disorder and one of the 
most frequent causes of mental impairment 
in the elderly (Barnes et al., 2003). It is 
characterized by the growth of senile 
plaques and neurofibrillar tangles, which 
are linked with neuronal loss (Cutler and 
Sramek, 2001). The past two decades have 
witnessed a considerable research endeavor 
devoted to unraveling the molecular, bio-
chemical, and cellular mechanisms of AD 
(Bartolucci et al., 2006). To date, several 
factors including amyloid-β (Aβ) deposits, 
oxidative stress, dyshomeostasis of biomet-
als and low levels of acetylcholine (ACh) 
have been demonstrated to be associated 
with AD pathogenesis, and several hypoth-
eses based on these factors have been pro-
posed to explain the mechanism of AD de-
velopment. Thus, new therapeutic advances 
that target these features of AD pathology 
and guarantee disease modification are cur-
rently under progress. 
EXCLI Journal 2013;12:1030-1042 – ISSN 1611-2156 
Received: September 04, 2013, accepted: October 20, 2013, published: December 13, 2013 
 
1031 
At present, management of AD patients 
continues to be primarily symptomatic, 
with cholinesterase (ChE) inhibitors as 
first-line remedy (Terry and Buccafusco, 
2003; Xie et al., 2013). On the other hand, 
changes in further neurotransmitter sys-
tems, mainly dopaminergic and seroto-
ninergic (Garcıá-Alloza et al., 2005; Terry 
et al., 2008) are also believed to be respon-
sible for the behavioral disorders found in 
AD patients (Dringenberg, 2000). This 
piece of information has led to the clue that 
monoamine oxidase inhibitors (IMAOs) 
might also be important for the treatment of 
AD (Bolea et al., 2011). Consequently, 
monoamine oxidase (MAO), flavine ade-
nine dinucleotide (FAD) containing enzyme 
which catalyze the α-carbon oxidation of a 
range of biogenic and xenobiotic amines 
(Strydom et al., 2013) is also a key target to 
be explored for the treatment of particular 
facets of this multifactorial disease (Bolea 
et al., 2011).  
Certainly, this multifunctional character 
of Alzheimer's disease (AD) offers the logi-
cal basis for the development of an innova-
tive drug design approach centered on mul-
titarget-directed-ligands (MTDLs) (Bolo-
gnesi et al., 2009; Cavalli et al. 2008; 
Youdim and Buccafusco, 2005). Therefore, 
the multitarget-directed ligand paradigm 
has been in the focus of growing attention 
by many research groups, which have de-
veloped a diversity of molecules acting on 
extremely dissimilar targets (Li et al., 2013; 
Costa et al., 2013; Elsinghorst et al., 2007). 
Multipotent ligands able to simultane-
ously inhibit cholinesterases, as well as 
MAOs, have been already developed in the 
context of a MTDL approach, leading to the 
discovery of HLA20, M30 and ladostigil, a 
brain selective molecule acting on different 
targets on the CNS which is in clinical trials 
for the treatment of AD (Passos et al., 
2013). 
Inspired by the particulars discussed 
above, we report herein design, synthesis, 
evaluation and molecular modeling studies 
of compounds as dual inhibitors, active 
against both acetylcholinesterase as well as 
monoamine oxidase. 
 
DESIGN OF MOLECULES 
It has been proved that derivatives of 1-
thiocarbamoyl-3-phenyl-5-thienyl-2-pyra-
zoline are active in micromolar range 
against both AChE and MAO-B (Ucar et 
al., 2005). One interesting compound “a” is 
shown in Figure 1. 
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Figure 1: Design concept of 1H-pyrazole 
derivatives as AChE and MAO inhibitors 
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Now, it has been shown that a high 
number of sp2 carbons and therefore the π 
orbitals, increases the molecular recognition 
by the AChE enzyme as the active site of 
AChE is composed of many aromatic ami-
no acids (Trujillo-Ferrara et al., 2003). 
This idea prompted us to aromatize the 
1H-pyrazole ring present in the molecule 
along with atom bioisosterism and replace 
the thienyl ring with 6-membered aromatic 
ring as the latter is present in tacrine and is 
involved in interactions with enzyme. Also, 
biological testing of some compounds with 
imine functionality has shown combined 
activities both on AChE and MAO. More 
importantly, the compounds appeared to be 
reversible MAO inhibitors, potentially de-
void of the undesirable side effect associat-
ed with the old irreversible inhibitors 
(Cavalli et al., 2008). So, imine functionali-
ty is also introduced into the structure. 
Keeping above facts in mind, various 
1H-pyrazole derivatives have been de-
signed as shown in Figure 1. 
RESULTS AND DISCUSSION 
Chemistry 
The synthetic path of the 3-aryl-1-
phenyl-1H-pyrazole derivatives (2a–3j) is 
demonstrated in Figure 2. Straightforward 
condensation of phenylhydrazine and 4-
haloacetophenone gave compounds 1a and 
1b which were further cyclized and 
formylated by means of familiar Vilsmeier-
Haack reagent (Youssef et al., 2010) to 
yield pyrazole carbaldehyde 2a and 2b. The 
needed products 3a-3g were obtained in 
good yield by reaction of either 2a or 2b 
with different amines in the presence of 
catalytic quantity of glacial acetic acid. 
Physicochemical characterization of the 
prepared compounds is given in Table 1. 
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Figure 2: Synthetic scheme for synthesis of designed compounds 
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Table 1: Physicochemical properties of the synthesized compounds 
Sr. no. Name of 
the  
compound 
X R Molecular  
formula 
Molecular 
weight 
Melting 
point (°C) 
%yield
1 2a -Cl - C16H11ClN2O 282.72 106-108 90 
2 2b -F - C16H11FN2O 266.27 110-112 86 
3 3a -Cl -CH3 C17H14ClN3 295.77 67-69 67 
4 3b -Cl -CH2CH3 C18H16ClN3 309.79 72-75 68 
5 3c -Cl -CH2CH2CH3 C19H18ClN3 323.82 78-79 62 
6 3d -Cl -CH2CH2OH C18H15ClN3O 325.79 142-143 71 
7 3e -Cl -C6H5 C22H16ClN3 357.84 86-88 82 
8 3f -F -CH3 C17H14FN3 279.31 65-67 61 
9 3g -F -CH2CH3 C18H16FN3 293.34 72-74 65 
10 3h -F -CH2CH2CH3 C19H18FN3 307.36 75-76 59 
11 3i -F -CH2CH2OH C18H16FN3O 309.34 139-142 78 
12 3j -F -C6H5 C22H16FN3 341.38 82-84 80 
 
 
Characterization of all the compounds 
was accomplished by the spectral (IR, 
NMR) means as well as elemental analysis 
and found to be in accord with their as-
signed chemical structures. For example, IR 
spectrum of the compound 3a revealed 
characteristic absorption band at 1662 cm-1 
due to imine (C=N) group. The pyrazole 
ring displayed three bands at 1451 cm-1, 
1491cm-1, 1111 cm-1 owing to (-C=C), 
(-C=N), (-N-N) groups respectively. The 
formation of imine was further confirmed 
by 1H NMR spectra which exhibited down-
field appearance of a singlet at δ 8.72. The 
pyrazole proton was verified by emergence 
of one singlet around δ 8.51. The multiplets 
between δ 7.26-7.86 substantiated the pres-
ence of aromatic protons. One singlet at δ 
2.75 proved three aliphatic protons.  
 
AChE inhibition evaluation 
The inhibitory activities of compounds 
2a, 2b and 3a-3j, against AChE (from mice) 
were measured according to the modified 
spectrophotometric method of Ellman et al. 
(Ellman et al., 1961; Vogel, 2002) with 
donepezil as reference compound.  
The AChE inhibition data (IC50 and 
pIC50 values) of the compounds under 
study is presented in Table 2. Interestingly, 
these results showed that AChE inhibitory 
activity of the compounds was in nanomo-
lar range and all compounds inhibited the 
enzyme successfully. Specially, compound 
3e and 3j, in which phenyl group was cou-
pled to pyrazole scaffold through imine 
linker, were the most effective inhibitors 
with pIC50 value of 4.2 and 4.14 respec-
tively which were comparable to the stand-
ard donepezil (pIC50 = 4.92). Inhibition 
potential of the molecules varied with the 
substituent on imine nitrogen. There was 
reduction in activity with increase in the 
length of the alkyl substituent (3a, pIC50 = 
   ö                 
and 3f, pIC50 = 3.86 >3g, pIC50 = 3.64 
>3h, pIC50 = 3.54). Moreover, addition of 
hydroxyl group enhanced the activity (3b, 
pIC50 = 3.64 <3d, pIC50 = 3.88). However 
placing phenyl group at this nitrogen was 
highly favorable for AChE inhibitory ac-
tivity (3e and 3j). Overall, chloro deriva-
tives were more potent than fluoro deriva-
tives. Further, introduction of imine func-
tionality augmented the activity as the two 
aldehydes under investigation were least 
effective (2a, pIC50 = 3.5, 2b, pIC50 = 3.6) 
with compound 3h as exception.  
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Table 2: In vitro AChE, MAO-A and MAO-B inhibitory activities of 1H-pyrazole derivatives and refer-
ence compound 
Sr. 
no. 
Compound IC50 (µM)a 
AChE 
pIC50 
(mM) 
AChE  
IC50 (µM)a 
MAO-A 
IC50 (µM)a 
MAO-B 
pIC50 
(mM) 
MAO-B 
SIb 
1 2a 0.32(±0.04) 3.5 15.46(±1.42) 1.03(±0.14) 2.99 15.01 
2 2b 0.25(±0.02) 3.6 10.82(±2.14) 0.28(±0.05) 3.56 38.64 
3 3a 0.13(±0.007) 3.90 * 0.95(±0.07) 3.02 >105.26c 
4 3b 0.15(±0.02) 3.82 * 1.37(±0.24) 2.86 >72.99 c 
5 3c 0.18(±0.04) 3.75 * 2.03(±0.45) 2.69 >49.26 c 
6 3d 0.12(±0.02) 3.92 * 0.60(±0.08) 3.22 >166.67c 
7 3e 0.06(±0.002) 4.2 * > 100 - - 
8 3f 0.14(±0.03) 3.86 * 0.34(±0.04) 3.47 >294.12c 
9 3g 0.23(±0.02) 3.64 * 0.57(±0.06) 3.24 >175.44c 
10 3h 0.29(±0.05) 3.54 * 0.72(±0.08) 3.14 >138.89c 
11 3i 0.13(±0.01) 3.88 * 0.38(±0.05) 3.43 >263.16c 
12 3j 0.07(±0.003) 4.14 * > 100 - - 
13 donepezil 0.01(±0.004) 4.92 * 25.52 1.59 >3.92 
a Each IC50 value is the mean ± S.D. of three experiments. 
b Selectivity index: MAO-B selectivity ratio [IC50 (MAO-A)]/[IC50 (MAO-B)]  
c Values calculated with the assumption that the corresponding IC50 against MAO-A is the highest concentration tested (100 µM). 
* Inactive at 100 µM (highest concentration tested) 
 
 
 
MAO inhibition study 
To complete the study of the multi-
potent biological profile of the designed 
compounds, the inhibitory activity against 
MAO-A and MAO-B was determined and 
compared with the inhibition exerted by the 
standard donepezil. 
MAO isoforms of goat liver were used 
to determine MAO-A and MAO-B inhibit-
ory activities of synthesized pyrazole deriv-
atives using reaction conditions described 
by Holt et al. (1997) with some modifica-
tions. Liver tissue was utilized to screen the 
MAO-inhibitory actions of these com-
pounds since liver was reported to be a fine 
source for both isoforms of the enzyme 
(Bayazit and Khan., 2005). 
The MAO-A, MAO-B inhibition data 
and the selectivity indexes (SI = IC50 
MAO-A/IC50 MAO-B) of the present 
compounds are reported in Table 2, togeth-
er with the results obtained for the reference 
used. 
Normally, the newly tested compounds 
selectively inhibited the enzymatic activity 
of MAO-B in the nanomolar or low mi-
cromolar range. The compounds 2a and 2b 
were active on both type of isoforms but 
selective towards MAO-B. Introducing sub-
stituted imino functionality in compounds 
resulted in molecules totally inactive on 
MAO-A enzyme. Most interesting com-
pounds from the series were 3f (pIC50 = 
3.47, SI = >294.12), 3i (pIC50 = 3.43, SI = 
>263.16) and 3d (pIC50 = 3.22, SI = 
>166.67). It is noteworthy that lengthening 
of alkyl chain on imine nitrogen resulted in 
diminished activity (3a, pIC50 = 3.02 >3b, 
pIC50 = 2.86 >3c, pIC50 = 2.69 and 3f, 
pIC50 = 3.47 >3g, pIC50 = 3.24 >3h, 
pIC50 = 3.14). Further substitution of this 
alkyl chain with hydroxyl group gave com-
pounds with enhanced activity and selectiv-
ity (3b <3d and 3g <3i). The positioning of 
phenyl group at imine nitrogen produced 
compounds 3e and 3j. This structural modi-
fication caused marked reduction in inhibi-
tory activity. In general, derivatives with p-
fluoro group were more effective inhibitors 
than with p-chloro group. Also, it is notable 
that transformation of aldehyde to imino 
was totally unfavourable in case of fluoro 
derivatives.  
 
Molecular modeling studies 
The foregoing studies point out that 
some compounds seem to be promising 
multitarget inhibitors. Nevertheless, they 
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also demonstrate unique trends in the 
pharmacological profile. It is unclear why 
the inhibitory potency against MAO-B and 
AChE is affected by the length of the side 
chain. Therefore, to shed light onto struc-
ture activity relationships and to identify 
the binding mode, a series of docking simu-
lations was conducted for all compounds to 
AChE and MAO-B. The X-ray crystallo-
graphic structures of AChE and MAO-B 
(PDB code: 1ACJ and 2V5Z) were re-
trieved from protein data bank. 3D struc-
tures of the all AChE inhibitors under study 
were docked into the active site of the pro-
teins. 
AChE inhibition: All compounds were 
bound primarily with the anionic subsite of 
catalytic active site. The ligands were af-
fixed in the active site with pi-pi interac-
tions. Remarkably, all AChE inhibitors 
were sandwiched between Trp84 and 
Phe330 by the contribution of aromatic 
rings. The interaction mode of the top dock-
ing pose of most active compound 3e with 
amino acids in the active site of AChE is 
depicted in Figure 3. The theoretical bind-
ing energy was not in accordance with the 
experimental results. However, the experi-
mental activity trend could be explained 
more or less by the number and the distance 
of pi-pi stacking interactions. As can be 
seen from Table 3 and Figure 3, compound 
3e had highest number of pi-pi stacking in-
teractions and all three aromatic rings were 
engaged in these. Also, its imine nitrogen 
was involved in hydrogen bonding with hy-
droxyl group of TYR121. Although its 
counterpart 3j possessed same type of bind-
ing but the distance of pi-pi interactions 
was lesser in case of compound 3e than 3j 
which could be the reason of its higher ac-
tivity as smaller distance might cause 
stronger interactions. More activity of all 
chloro derivatives can be explained on the 
similar rationale. In case of compounds 
other than 3e and 3j, simply 1H-pyrazole 
and 3-phenyl rings were involved in pi-pi 
interactions which might have been the 
cause of their reduced activity. Further 
within both series the activity decreased 
with increase in interaction distance (except 
3d, 3i and 3g). The higher inhibitory poten-
tial of 3d and 3i than 3a, 3b and 3f, 3g re-
spectively can be attributed to one extra hy-
drogen bond formed between hydroxyl hy-
drogen of both compounds and Gly117 
(Figure 4). However, the anomalous behav-
iour of 2a, 2b and 3g could not be put in 
plain words. 
 
 
Table 3: Docking results of derivatives on both enzymes AChE and MAO-B 
Sr. 
no. 
Compound AChE amino acids 
involved in pi-pi in-
teractions (No. of in-
teractions) 
Total distance 
of pi-pi interac-
tions 
AChE theoreti-
cal binding en-
ergy (Kcal/mol) 
MAO-B  
theoretical 
binding energy 
(Kcal/mol) 
1 2a Trp84 and phe330 (6) 27.517 -10.2 -8.1 
2 2b Trp84 and phe330 (6) 27.557 -10.5 -9.6 
3 3a Trp84 and phe330 (6) 27.471 -10.5 -8.2 
4 3b Trp84 and phe330 (6) 27.723 -10.3 -7.6 
5 3c Trp84 and phe330 (6) 27.859 -10.0 -7.5 
6 3d Trp84 and phe330 (6) 27.754 -10.4 -8.2 
7 3e Trp84 and phe330 (7) 33.734 -10.2 -5.5 
8 3f Trp84 and phe330 (6) 27.736 -10.9 -9.1 
9 3g Trp84 and phe330 (6) 27.714 -10.6 -8.8 
10 3h Trp84 and phe330 (6) 27.899 -10.4 -8.8 
11 3i Trp84 and phe330 (6) 27.802 -10.6 -8.3 
12 3j Trp84 and phe330 (7) 33.898 -10.4 -6.4 
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Figure 3: H-bond and pi-pi interactions of 
compound 3e with AChE 
 
 
(a) 
 
(b) 
 
Figure 4: 2D depiction of interactions of com-
pounds (a) 3d and (b) 3i with active site of 
AChE 
 
 
MAO-B inhibition: In this study, theo-
retical binding affinity was in very good 
correlation with the observed activity (cor-
relation coefficient = 0.865). Therefore 
structure activity relationships can be well 
described using this score. Binding mode of 
most selective compounds 3f, 3i ad 3d is 
discussed herein and shown in Figure 5. 
The docked compounds exhibited signifi-
cant contacts with the active site residues. 
Compound 3f was marvelously accommo-
dated in Aromatic Cage (FAD, TYR398 
and TYR435) and its 3-phenyl ring dis-
played pi-pi interactions with TYR398. Its 
imine nitrogen formed hydrogen bond with 
hydroxyl group of TYR435. Nitrogen at 2nd 
position of pyrazole ring made hydrogen 
bond with GLN206. Also, fluoro group is 
involved in hydrogen bonding with FAD. 
The other two aromatic rings were embed-
ded in Narrow Hydrophobic Cavity com-
prising of amino acid residues like ILE198 
and ILE199. Compound 3i and 3d did not 
show any pi-pi interactions. Their imine 
nitrogen established hydrogen bonds with 
thiol group of CYS172 and hydroxyl group 
of TYR435. Hydroxyl group of these com-
pounds created contacts with TYR435 and 
TYR188 through hydrogen bonding. Fur-
ther these compounds generated hydrogen 
bond interactions with FAD. The activity of 
the compounds decreased with increase in 
the distance from FAD (3f, 3.44 Ao <3i, 
3.61Ao <3d, 3.62 Ao). 
 
Figure 5(a) 
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(b) 
 
(c) 
Figure 5: Interactions of compounds (a) 3f (b) 
3i and (c) 3d with MAO-B active site containing 
FAD (ball and stick model) 
 
EXPERIMENTAL WORK 
All the starting materials and reagents 
used were of analytical grade and utilized 
without any further purification. The melt-
ing points were determined with Decible 
Melting Point apparatus and are uncorrect-
ed. The reactions were checked by thin lay-
er chromatography (TLC) using silica gel G 
as stationary phase. Infrared spectra were 
recorded with Perkin Elmer IR spectropho-
tometer (KBr disks). Proton nuclear mag-
netic resonance spectra (1H NMR) were 
taken on Bruker Avance 400 MHz NMR 
instrument. Chemical shifts are expressed 
as δ values (ppm), downfield from tetrame-
thyl silane (TMS) used as internal standard. 
Splitting patterns are given as s, singlet; d, 
doublet; t, triplet; m, multiplet. 
 
Chemistry 
Procedure for synthesis of phenyl  
hydrazones (1a, 1b) 
To a solution of the appropriate aceto-
phenone (0.04 mol) in 20 mL methanol, 
phenyl hydrazine (0.04 mol) and glacial 
acetic acid (1 mL) were added. The result-
ing solution was shaken for ten minutes at 
room temperature. The precipitates of hy-
drazone were filtered and washed with suf-
ficient amount of methanol. 
 
Procedure for synthesis of 3-aryl-1-phenyl-
1H-pyrazole-4-carbaldehyde (2a, 2b)  
POCl3 (0.06 mol) was added dropwise 
to an ice-cold stirred solution of hydrazone 
(1a or 1b) (0.02 mol) in anhydrous DMF 
(25 mL). Following complete addition of 
POCl3, the reaction mixture was allowed to 
attain room temperature and then heated at 
60-70 °C for 3-4 h. The resulting mixture 
was poured onto crushed ice, neutralized 
with dilute sodium hydroxide. The precipi-
tate obtained were filtered, washed with 
sufficient quantity of water and recrystal-
ized from chloroform.  
3-(4-chorophenyl)-1-phenyl-1H-
pyrazole-4-carbaldehyde (2a):  IR (KBr, 
cm-1) ν max: 3042 (Ar-CH), 1664 
(C=N),1450, 1493, 1114 (-C=C), (-C=N), 
(-N-N) pyrazole; 1H NMR (400 MHz, 
CDCl3, δ ppm):  10.02 (s, 1H, –CH=O), 
8.51 (s, 1H, Pyrazole-CH), 7.11–7.88 (m, 
9H, Ar- H); Anal. Required: C, 67.97; H, 
3.92; N, 9.91; Found: C, 67.92; H, 3.95; N, 
9.96. 
3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-carbaldehyde (2b):  IR (KBr, 
cm-1) ν max: 3040 (Ar-CH), 1665 
(C=N),1451, 1491, 1111 (-C=C), (-C=N), 
(-N-N) pyrazole; 1H NMR (400 MHz, 
CDCl3, δ ppm):  10.05 (s, 1H, –CH=O), 
8.51 (s, 1H, Pyrazole-CH), 721–7.87 (m, 
9H, Ar- H); Anal. Required: C, 72.17; H, 
7.14; N, 10.52. Found: C, 72.12; H, 7.16; 
N, 10.58. 
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Procedure for synthesis of Schiff bases of 3-
aryl-1-phenyl-1H-pyrazole-4-carbaldehyde 
(3a-3j)  
3-Aryl-1-phenyl-1H-pyrazole-4-carbal-
dehyde (0.02 mol), the appropriate amine 
(0.04 mol) and catalytic amount of glacial 
acetic acid were taken in anhydrous metha-
nol and stirred for 72 h at room temperature 
in case of 3a-3c and 3f-3h whereas refluxed 
for 06 h for others. The resulting precipi-
tates were filtered, re-crystallized from eth-
anol and dried at room temperature in des-
iccator. 
N-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) methanamine 
(3a): IR (KBr, cm-1) ν max: 3041 (Ar-CH), 
1662 (C=N),1451, 1491, 1111 (-C=C), 
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.72 (s, 1H,  
–CH=N), 8.51 (s, 1H, Pyrazole-CH), 7.26–
7.86 (m, 9H, Ar- H), 2.75 (s, 3 H, =NCH3); 
Anal. Required: C, 69.01; H, 11.93; N, 
14.24. Found: C, 69.04; H, 11.91; N, 14.23. 
N-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) ethanamine (3b): 
IR (KBr, cm-1) ν max: 3037 (Ar-CH),1659 
(C=N),1453, 1492, 1110 (-C=C), (-C=N), 
(-N-N) pyrazole; 1H NMR (400 MHz, 
CDCl3, δ ppm):  8.73 (s, 1H, –CH=N), 8.52 
(s, 1H, Pyrazole-CH), 7.24–7.80 (m, 9H, 
Ar- H), 2.72 (q, 2 H, =NCH2); 1.3 (t, 3 H, 
CH3); Anal. Required: C, 69.79; H, 5.21; N, 
13.56. Found : C, 69.75; H, 5.27; N, 13.53. 
N-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) propan-1-amine 
(3c): IR (KBr, cm-1) ν max: 3035 (Ar-CH), 
1664(C=N),1455, 1491, 1112 (-C=C), 
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.68 (s, 1H,  
–CH=N), 8.51 (s, 1H, Pyrazole-CH), 6.20–
7.79 (m, 9H, Ar- H), 2.74 (t, 2 H, =NCH2); 
1.2 (m, 2 H, CH2) 0.93 (t, 3 H, CH3); Anal. 
Required: C, 70.47; H, 5.60; N, 
12.98.Found: C, 70.44; H, 5.69; N, 12.92. 
N-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) ethanolamine 
(3d): IR (KBr, cm-1) ν max: 3037 (Ar-CH), 
1663 (C=N),1453, 1492, 1110 (-C=C),  
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.70 (s, 1H,  
–CH=N), 8.52 (s, 1H, Pyrazole-CH), 7.19–
7.81 (m, 9H, Ar- H), 3.11- 3.42 (m, 4H, 
CH2); Anal. Required: C, 66.36; H, 4.95; N, 
12.90; Found: C, 66.38; H, 4.95; N, 12.96.  
N-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) benzenamine 
(3e): IR (KBr, cm-1) ν max: 3034 (Ar-CH), 
1663(C=N),1455, 1496, 1111 (-C=C), 
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.69 (s, 1H,  
–CH=N), 8.50 (s, 1H, Pyrazole-CH), 7.19–
7.82 (m, 14H, Ar- H); Anal. Required: C, 
73.84; H, 4.51; N, 11.74 Found:C, 73.81; 
H, 4.55; N, 11.78. 
N-((4-fluorophenyl)-1-phenyl-1H-pyra-
zole-4-yl) methylene ) methanamine (3f): 
IR (KBr, cm-1) ν max: 3042 (Ar-CH), 1661 
(C=N),1453, 1489, 1113 (-C=C), (-C=N), 
(-N-N) pyrazole; 1H NMR (400 MHz, 
CDCl3, δ ppm):  8.71 (s, 1H, –CH=N), 8.53 
(s, 1H, Pyrazole-CH), 7.22–7.85 (m, 9H, 
Ar- H), 2.75 (s, 3 H, =NCH3); Anal. 
Required: 73.10; H, 5.05; N, 15.04. Found: 
C, 73.12; H, 5.07; N, 15.02. 
N-((3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) ethanamine (3g): 
IR (KBr, cm-1) ν max: 3040 (Ar-CH),1659 
(C=N),1451, 1495, 1112 (-C=C), (-C=N), 
(-N-N) pyrazole; 1H NMR (400 MHz, 
CDCl3, δ ppm):  8.73 (s, 1H, –CH=N), 8.51 
(s, 1H, Pyrazole-CH), 7.21–7.80 (m, 9H, 
Ar- H), 2.73 (q, 2 H, =NCH2); 1.3 (t, 3 H, 
CH3); Anal. Required: C, 73.70; H, 5.50; N, 
14.32;Found: C, 73.72; H, 5.55; N, 14.30. 
N-((3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) propan-1-amine 
(3h): IR (KBr, cm-1) ν max: 3041 (Ar-CH), 
1660(C=N),1458, 1490, 1110 (-C=C), 
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.67 (s, 1H,  
–CH=N), 8.50 (s, 1H, Pyrazole-CH), 7.21–
7.82 (m, 9H, Ar- H), 2.75 (t, 2 H, =NCH2); 
1.2 (m, 2 H, CH2)0.95 (t, 3 H, CH3); Anal. 
Required: C, 74.25; H, 5.90; N, 13.67. 
Found: C,74.23; H, 5.91; N, 13.61. 
N-((3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) ethanolamine 
(3i): IR (KBr, cm-1) ν max: 3035 (Ar-
CH),1660 (C=N),1450, 1491, 1114 (-C=C), 
(-C=N),(-N-N) pyrazole; 1H NMR (400 
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MHz, CDCl3, δ ppm):  8.70 (s, 1H,  
–CH=N), 8.52 (s, 1H, Pyrazole-CH), 7.21–
7.79 (m, 9H, Ar- H), 3.12- 3.40 (m, 4H, 
CH2); Anal. Required: C, 69.89; H, 5.21; N, 
13.58; Found: C, 69.84; H, 5.22; N, 13.55. 
N-((3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole-4-yl) methylene) benzenamine 
(3j): IR (KBr, cm-1) ν max: 3034 (Ar-CH), 
1663(C=N),1455, 1496, 1111 (-C=C), 
(-C=N), (-N-N) pyrazole; 1H NMR (400 
MHz, CDCl3, δ ppm):  8.69 (s, 1H,  
–CH=N), 8.50 (s, 1H, Pyrazole-CH), 7.19–
7.82 (m, 14H, Ar- H); Anal. Required: C, 
77.40; H, 4.72; N, 12.31; Found: C, 77.42; 
H, 4.71; N, 12.37. 
 
Biochemistry 
Acetylcholinestrase inhibition assay  
Spectrophotometric Ellman’s method 
was used for determination of inhibitory 
activities (IC50 values) of synthesized de-
rivatives 2a-3j against mice AChE using 
donepezil as reference compound.  
Adult male Swiss albino mice (25±5 g) 
were procured from the Disease Free Small 
Animal House, Lala Lajpat Rai University 
of Veterinary & Animal Sciences 
(LLRUVAS), Hisar (Haryana). The exper-
imental protocol for animal studies was 
consented by Institutional Animal Ethics 
Committee (IAEC). The animals were 
housed in the animal house facility of the 
Department of Pharmaceutical Sciences, 
G.J.U S & T, Hisar, under standard condi-
tions of temperature (25±2 °C) and 
12 hr/12 hr light/dark cycles. The animals 
were kept under laboratory conditions for 
one week before beginning of the experi-
ments and permitted food and water ad libi-
tum. 
Male Swiss albino mice were decapitat-
ed; brain was rapidly dissected on ice, 
weighed and homogenized in 19 volumes 
(about 7 mg protein/ml) of 0.05 M 
NaH2PO4, pH 7.2. To 4 mL of the vehicle 
or different concentrations of the test com-
pound, 100 μL aliquot of this suspension 
was added and reincubated for 10 min at 
37 °C.  
A stock solution of the test compound 
(2 mM in dimethylsulfoxide) was made and 
diluted to required volume using 0.5 mM 
DTNB reagent. Sequential dilutions (1:10) 
of the compounds were prepared so as to 
attain the final concentration of 10–4 M and 
checked for activity. If active, IC50 values 
were determined from the inhibitory activi-
ty of succeeding concentrations. 
Blank, control and test samples were in-
cubated for 150 s with acetylthiocholine 
iodide (10 mM) and production of the yel-
low anion of 5-thio-2-nitrobenzoic acid was 
measured with Systronics 108 UV-visible 
spectrophotometer at 412 nm. 
The percentage inhibition was calculat-
ed by the following formula: %inhibition = 
Absorbance of control-Absorbance of in-
hibitor/Absorbance of control x 100. Re-
sponse-logarithm of inhibitor concentration 
curves were plotted for all compounds and 
the IC50 values were determined with Bio-
ToolKit320 (BioToolKit320, 2005). Results 
are expressed as the mean ± SD of at least 
three different experiments. 
 
Measurement of MAO activity 
The synthesized compounds were also 
screened for their activity at MAO-B and 
MAO-A using in vitro techniques. 
MAO was purified from the goat liver 
(100-150 g). Liver samples of goat were 
purchased from local market immediately 
after sacrifice. Homogenates of liver were 
prepared with 1:25 (w/v) in ice-cold potas-
sium phosphate buffer, pH 7.4 with a me-
chanical homogenizer. Homogenates were 
centrifuged at 1000 g, at 4 °C for 15 min 
and the supernatant was used as the source 
of MAO and kept at -70 °C. Since, MAO-A 
activity decreased rapidly following ho-
mogenization, freshly prepared homoge-
nates were used in studies of MAO-A activ-
ity (Bayazit and Khan, 2005). 
MAO activity was evaluated spectro-
photometrically according to the method of 
Holt et al. (1997). Homogenates were incu-
bated with the substrate p-tyramine 
(500 µM to measure MAO-A and 2.5 mM 
to measure MAO-B) following the inhibi-
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tion of one of the MAO isoforms with se-
lective inhibitors. Aqueous solutions of 
clorgyline or pargyline (500 nM), as selec-
tive MAO-A and -B inhibitor, were added 
to homogenates. Homogenates were incu-
bated with these inhibitors at 37 °C for 
60 min earlier to activity determination. Af-
ter incubation with test compounds (10 nM 
- 100 µM) or control, the MAO reactions 
were started and the reactions were incu-
bated at 37 °C. The assay mixture contained 
a 150 µL chromogenic solution (1 mM va-
nillic acid, 500 µM 4-aminoantipyrine, and 
4 U mL-1 peroxidase in 0.2 M potassium 
phosphate buffer, pH 7.6) 600 µL substrate 
solution (500 µM p-tyramine), and 150 µL 
potassium phosphate buffer, pH 7.6. The 
mixture was preincubated at 37 °C for 
10 min before the addition of enzyme. Re-
action was initiated by adding the homoge-
nate (100 µL), and absorbance was moni-
tored at 498 nm at 37 °C after 60 min. The 
results were expressed as IC50 and pIC50 
values. 
 
Molecular modeling  
The 2D structures of compounds were 
built with MavinSketch (MavinSketch 
5.10.1., 2012) and explicit hydrogens were 
added. Afterward these structures were op-
timized, changed into 3D and cleaned with 
gradient optimization. The resulting struc-
tures were saved in pdb format. The X-ray 
crystallographic structures of AChE along 
with tacrine and MAO-B with inhibitor 
Safinamide (PDB ID: 1ACJ and 2V5Z) 
were obtained from Brookhaven Protein 
Databank (http://www.rcsb.org/pdb). Molec-
ular modeling software UCSF Chimera 
(Pettersen et al., 2004) was employed for 
preparation of protein for docking. All sol-
vent molecules and co-crystallized ligands 
except FAD (2V5Z) were removed and im-
perfect side chains were completed using 
Dunbrack rotamer library (Dunbrack, 
2002). After that hydrogens were added and 
Gasteiger charges were computed with 
ANTECHAMBER (Wang et al., 2006). The 
prepared molecules were saved in pdb files 
for further workout. These structures of lig-
ands and proteins were changed into pdbqt 
format by means of AutoDock tools (Au-
toDock Tools 1.5.6 rc2). 
Docking simulations were performed 
with AutoDock Vina (Trott and Olson, 
2010) program. The Vina search space ap-
plied was center_x = 4.34518462891, cen-
ter_y = 69.9038811926, center_z = 
65.7756741596, size_x = 25.0, size_y = 
25.0, size_z = 25.0 for 1ACJ and center_x = 
52.1640844198 center_y = 155.977828543 
center_z = 27.8383407001 size_x = 
22.5898271723 size_y = 25.0 size_z = 
4.3118371451 for 2V5Z. The exhaustive-
ness was set to be 8. 
Validation of the docking protocols was 
done with reported crystal structures of pro-
tein-ligand complexes. The root-mean 
square deviation (RMSD) amongst the con-
formations of the Tacrine and Safinamide 
from the X-ray crystal structure and those 
from the results of AutoDock Vina was less 
than 1 Å, recommending that the parame-
ters chosen for the AutoDock Vina simula-
tion were practical to imitate the X-ray 
structures. These docking protocols were 
employed for docking of the compounds 
under investigation into the binding pocket 
of target enzymes. Final results were visual-
ized with the help of Discovery Studio 
(Discovery Studio v3.5 client, 2012). 
 
CONCLUSION 
In the present study, a new family of 
multitarget molecules able to interact with 
AChE as well as MAO-B has been synthe-
sized and evaluated. Moreover, a brief idea 
regarding their structure activity relation-
ship was drawn and significance of differ-
ent substitutions predominantly at imine 
nitrogen was studied. Presence of any sub-
stitution at imine nitrogen improved the 
AChE inhibitory activity and altered the 
selectivity in the direction of MAO-B. The 
binding mode analysis of compounds with 
the assistance of molecular docking simula-
tions bestowed imperative insights about 
their molecular recognition process. The 
data of this research suggests these mole-
cules as promising leads for the develop-
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ment of novel MTDL with a good AChE 
and MAO-B inhibitory potency, which are 
presently missing in the therapeutic arsenal. 
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